Narcan challenge. See naloxone challenge test
missed doses, 85
Narcotic Addict Treatment Act of 1974, 21, 25
mobile treatment units, 90
narcotics farms, 15
models of care, 202
Narcotics Register, New York City, 16
money management, 60
monotherapy tablets, 69
Narcotic Treatment Programs: Best Practice
Guideline, 237
morphine, 12˝17
National Institutes of Health consensus panel
duration of action, 217
recommendations, 4, 20
and neonatal abstinence syndrome, 219
necrotizing fasciitis, 163˝164
and pain management, 174˝175
Neonatal Abstinence Score, 219
motivational enhancement, 130
neonatal abstinence syndrome, 216, 218˝219
motivational interviewing, 53
and buprenorphine, 220˝221
Motivational Interviewing: Preparing People
and methadone, 219
for Change, 130
nicotine, effects of, 185
motivation for seeking treatment, 54, 96, 107,
and pregnancy, 212
191
node-link mapping, 128
multidisciplinary treatment team, 100
nonmalfeasance, principle of medical ethics,
multiple substance use, 48, 106, 111
298
and co-occurring disorders, 181
nutrition, and pregnancy, 223˝224
and dosage adjustments, 187
Nyswander, Dr. Marie E., 17
and increased drug testing, 188
management of, 186
O
and morbidity and mortality, 181
and pregnancy, 217
OBOT. See office-based opioid treatment
prevalence of, 180, 181
observed dosing, 65˝66
and psychosocial treatment services, 187˝188
office-based opioid treatment, 6, 63, 85, 90
mu opiate receptors, 28, 29
with methadone, 115
and buprenorphine, 30
opioid addiction
and methadone, 29
diagnosing in pregnant patients, 212
and naltrexone, 30
history of, 11˝12
mutual-help programs
as a medical disorder, 3˝5
and conflict with MAT, 135
opioid agonist, 64
and patient˝treatment matching, 88
definition, 28
for people with co-occurring disorders, 203
side effects of, 34
Web sites for, 136, 203
opioid analgesic abuse, 14
opioid antagonist, 5, 19
N
and diagnosing addiction in pregnant
women, 212
naloxone-buprenorphine combination. See
buprenorphine, SuboxoneĂ
side effects of, 34
opioid overdose, 50
naloxone challenge test, 50, 70
opioid pharmacotherapy
naltrexone, 5
contraindications to, 64˝65
development of, 19
stages of, 65
dosage forms, 32
opioid treatment programs
dose levels, 72
administrative considerations, 225
efficacy of, 33
attendance requirements, 124
induction stage of pharmacotherapy, 70
and co-occurring medical and mental
and overdose, 42
disorders, 91
pharmacology and pharmacotherapy of, 30˝31
definition, 2
safety of, 42
and duty to warn, 202
side effects of, 35
324
Index